Introduction {#s1}
============

There has been no meaningful decrease in the time from symptom onset to diagnosis of pulmonary hypertension (PH) in the past 20 years. Therefore, the diagnostic algorithm and guidelines for screening at-risk groups have been modified, balancing the benefits of earlier diagnosis and disease recognition against the economic healthcare burden of additional screening and increased referrals to PH centres.

Diagnostic approach in patients with clinical suspicion for PH/pulmonary arterial hypertension {#s2}
==============================================================================================

PH due to parenchymal, cardiac, thromboembolic and other diseases (diagnostic groups 2, 3, 4 and 5, respectively) is associated with worse outcomes and limited treatment options, resulting in referral of these patients to PH centres. Guidelines for the diagnosis and management for these subgroups are addressed separately by the relevant 6th World Symposium on Pulmonary Hypertension (WSPH) Task Force articles in this issue of the *European Respiratory Journal* \[[@C1]--[@C3]\].

Clinical suspicion of PH {#s2a}
------------------------

### Symptoms {#s2a1}

Symptoms of PH are non-specific: exertional dyspnoea, fatigue, weakness, chest pain, light-headedness/syncope and, less frequently, cough. Progressive right-sided heart failure (oedema, ascites, abdominal distension) occurs in later or more accelerated disease. Rarely, haemoptysis, Ortner\'s syndrome/hoarseness (unilateral vocal chord paralysis) and arrhythmias may characterise PH.

### Physical findings {#s2a2}

Physical findings include augmented second heart sound (P2 component), right ventricular lift, jugular venous distension, hepatojugular reflux, ascites, hepatomegaly and/or splenomegaly, oedema, tricuspid regurgitant or pulmonary regurgitant murmurs, and S3 gallop.

Diseases associated with PH can be suggested by history and physical exam.

Established diagnostic tools {#s2b}
----------------------------

### Electrocardiography {#s2b1}

Since the US National Institutes of Health (NIH) registry report on primary PH in 1987 \[[@C4]\], the ECG has been considered a reliable clue to the presence of PH. ECG features in patients with pulmonary arterial hypertension (PAH) have been demonstrated to be associated with worse prognosis \[[@C5], [@C6]\]. The derivative populations for these conclusions were patients with known PAH, predominantly World Health Organization Functional Class III and IV. The utility of the ECG as a screening tool in complicated patients or those early in the course of their disease is uncertain. A normal ECG does not exclude PH.

### Blood tests and immunology {#s2b2}

Blood tests are not useful for PH diagnosis, but distinguish some forms of PH and indicate end-organ compromise. Routine biochemistry, haematology and thyroid function tests are required in all patients. Liver function abnormalities may represent congestion, primary liver disease and/or consequences of therapy. Thyroid disease is common in PAH, may develop during the disease and should be considered in cases of abrupt deterioration. Elevations of brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are associated with right ventricular overload, and are predictors of worse outcome.

Routine screening for connective tissue disease (CTD), hepatitis and HIV is required. Elevated antinuclear antibodies (ANAs) occur frequently, although in low titres (1:80). Recommended serological testing for scleroderma includes ANAs (as ELISA can be associated with false-negative tests, ANA immunofluorescence is recommended and should be considered positive at ≥1:160). If there is a high index of suspicion, consider a panel that consists of anticentromere, antitopoisomerase, anti-RNA polymerase III, double-stranded DNA, anti-Ro, anti-La and U1-RNP antibodies.

Patients with CTD (associated with thombophilic states) and chronic thromboembolic PH (CTEPH) should undergo screening for coagulopathies and thrombophilia, including anticardiolipin antibodies, lupus anticoagulant and anti-β~2~-glycoprotein antibodies.

### Pulmonary function tests and arterial blood gases {#s2b3}

Pulmonary function tests are addressed in the PH lung disease Task Force article in this issue of the *European Respiratory Journal* \[[@C2]\], and should include total lung capacity and diffusing capacity of the lung for carbon monoxide (*D*~LCO~). In most patients with PAH there is a mild restrictive component. Marked reduction in *D*~LCO~ (\<60% of predicted) or severe exertional hypoxaemia can indicate pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis \[[@C7]\].

### Cardiopulmonary exercise testing {#s2b4}

Cardiopulmonary exercise testing (CPET) for diagnostic purposes can be done non-invasively or with haemodynamic testing \[[@C8]\]. CPET can quantify the degree of relative hypoperfusion of the lung and the systemic circulation that occurs during exercise in patients with PH \[[@C9]\], and can grade the severity of exercise limitation and assess responses to therapy \[[@C10]\].

Abnormalities in effort-independent ratio of minute ventilation to carbon dioxide production (*V̇*~E~/*V̇*~CO~2~~) and end-tidal carbon dioxide tension (*P*~ETCO~2~~) obtained during CPET have been used to estimate the likelihood of PH (lower peak oxygen uptake (*V̇*~O~2~~) and/or higher *V̇*~E~/*V̇*~CO~2~~ signifying an increasing likelihood of pulmonary vascular disease) \[[@C11]\]. Several investigators have demonstrated the utility of CPET in defining abnormal exercise responses specific to PAH \[[@C12]--[@C15]\]. CPET can be particularly useful in helping identify the predominant underlying cardiopulmonary pathophysiology \[[@C13], [@C16]--[@C19]\]. A detailed description of the methodologies used in CPET for PH can be found in S[un]{.smallcaps} *et al.* \[[@C9]\]. Submaximal exercise testing to evaluate PAH severity using a simplified gas exchange system has also been proposed \[[@C20]\].

Accurate utilisation of CPET requires performance by a competent facility and interpretation by a clinician with expertise in gas exchange in conjunction with the patient\'s history, physical and laboratory findings. CPET is useful for determining the nature of the exercise limitation in patients with unexplained dyspnoea, but should not be used as the sole screening tool for asymptomatic subjects at risk for developing PAH; CPET can help evaluate cardiopulmonary limitations and assess pulmonary vascular involvement in these patients; emerging evidence suggests that CPET may be useful for evaluating symptomatic patients at high risk for developing PAH \[[@C15]\]. In addition, CPET should be considered after diagnosis of PAH to quantify the severity of exercise impairment and to estimate prognosis.

### Transthoracic echocardiography {#s2b5}

The transthoracic echocardiogram (TTE) remains the most important non-invasive screening tool and right heart catheterisation (RHC) remains mandatory to establish the diagnosis.

The echocardiographic probability of PH was derived from previously published data in normal adults \[[@C21]--[@C23]\], and consolidated by expert opinion using the combination of tricuspid regurgitant velocity, right ventricular size, interventricular septal function, inferior vena cava diameter fluctuations with respiratory cycle, systolic right atrial area, pattern of systolic flow velocity and early diastolic pulmonary regurgitant velocity, and diameter of the pulmonary artery ([tables 1](#TB1){ref-type="table"} and [2](#TB2){ref-type="table"}) \[[@C24]--[@C27]\].

###### 

Echocardiographic probability of pulmonary hypertension (PH) in symptomatic patients with a suspicion of PH

  --
  --

^\#^: see table 2. Reproduced and modified from \[[@C24]\] with permission.

###### 

Echocardiographic signs suggesting pulmonary hypertension (PH) used to assess the probability of PH in addition to tricuspid regurgitation velocity measurement in [table 1](#TB1){ref-type="table"}

                                                **A: The ventricles**                                                                                  **B: Pulmonary artery**                                                                          **C: Inferior vena cava and right atrium**
  ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
                              Right ventricle/left ventricle basal diameter ratio \>1.0                               Right ventricular outflow Doppler acceleration time \<105 ms and/or mid-systolic notching   Inferior cava diameter \>21 mm with decreased inspiratory collapse (\<50% with a sniff or \<20% with quiet inspiration)
   Flattening of the interventricular septum (left ventricular eccentricity index \>1.1 in systole and/or diastole)                Early diastolic pulmonary regurgitation velocity \>2.2 m·s^--1^                                                      Right atrial area (end-systole) \>18 cm^2^
                                                                                                                                                  Pulmonary artery diameter \>25 mm                              

Echocardiographic signs from at least two different categories (A/B/C) from the list should be present to alter the level of echocardiographic probability of PH. Reproduced and modified from \[[@C24]\] with permission.

### Ventilation/perfusion lung scanning {#s2b6}

Ventilation/perfusion (*V/Q*) lung scanning is addressed in the CTEPH Task ‌Force ‌article in this issue of the *‌European ‌Respiratory ‌Journal* \[[@C3]\]. A normal *V/Q* scan remains the preferred diagnostic tool and rules out CTEPH. Nuclear medicine societies are recommending a transition of *V/Q* reporting to a binary interpretation \[[@C28], [@C29]\].

### Chest computed tomography {#s2b7}

Chest computed tomography (CT) demonstrating right ventricular dilation, right atrial dilation, enlarged main pulmonary artery (diameter ≥29 mm) or a main pulmonary artery/ascending aorta diameter ratio ≥1 is suggestive of PH \[[@C30]\]. High-resolution non-contrast examination can identify parenchymal lung disease and discriminate between PH lung disease and PAH (group 3 *versus* group 1).

Current state-of-the-art diagnostic algorithm {#s3}
=============================================

The modified diagnostic algorithm divides the diagnostic approach into 1) that undertaken outside the PH expert centre, including recommendations for high-risk/accelerated disease requiring expedited triage to the expert centre ([figure 1](#F1){ref-type="fig"}), and 2) that focusing on the diagnosis of PH once referred to a PH expert centre ([figure 2](#F2){ref-type="fig"}).

![Algorithm for the diagnosis of pulmonary hypertension (PH) and its causes: triage of urgent cases and diagnosis of common conditions (for more details, see the accompanying text). *V/Q*: ventilation/perfusion; CTEPH: chronic thromboembolic PH. ^\#^: described in the 2015 European Society of Cardiology/European Respiratory Society PH guidelines \[[@C24]\]; ^¶^: these include chronic thromboembolic disease without PH, which should be considered in patients with risk factors and/or previous venous thromboembolism; ^+^: single photon emission computed tomography or planar *V/Q* scan is acceptable (interpretation is binary: normal or abnormal); ^§^: see algorithms for left heart disease and lung disease/hypoxia-related PH \[[@C1]--[@C3]\], which provide details of further management of these patients; ^ƒ^: referral of a patient to be seen in person or for a teleconsultation.](ERJ-01904-2018.01){#F1}

![Algorithm for the diagnosis of pulmonary hypertension (PH) and its causes: role of the PH expert centre. CTEPH: chronic thromboembolic PH; *V/Q*: ventilation/perfusion; RHC: right heart catheterisation. ^\#^: single photon emission computed tomography or planar *V/Q* scan is acceptable; ^¶^: these include patients with chronic thromboembolic disease without PH; ^+^: the composition of the multidisciplinary team may differ depending on the type of clinical problem; ^§^: according to clinical classification of PH; ^ƒ^: only in expert centres and only with a reassessment plan in place.](ERJ-01904-2018.02){#F2}

Practice recommendations (including high-risk population screening recommendations) {#s4}
===================================================================================

Patients with congenital heart disease (CHD), CTD, HIV and portopulmonary hypertension (POPH) are at increased risk for PH. As little or no progress has been made in earlier diagnosis, this Task Force recommends more aggressive assessment and screening of some of these high-risk populations.

Scleroderma (systemic sclerosis) and scleroderma spectrum {#s4a}
---------------------------------------------------------

The 5th WSPH report, the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) PH guidelines and the NIH-supported 2013 CTD-PAH guidelines recommend annual screening in patients with systemic sclerosis (SSc) \[[@C24], [@C31], [@C32]\]. All guidelines recommend the DETECT algorithm (evidence-based detection of PAH in SSc) in patients with SSc spectrum disorders (SSc, mixed CTD or other CTDs with prominent scleroderma features (*e.g.* sclerodactyly, nail fold capillary abnormalities and SSc-specific autoantibodies)) associated with *D*~LCO~ \<60% of predicted and disease duration \>3 years. The current diagnosis Task Force undertook a systematic review of the published literature for screening tools available for CTD-PAH \[[@C33]\]. The review supports incorporating TTE, DETECT (with preliminary data on its performance with those with *D*~LCO~ \<80% of predicted) or forced vital capacity (FVC)/*D*~LCO~ ratio \>1.6 and blood markers (such as NT-proBNP) in SSc spectrum disorders. Based on this data and on the published guidelines, this Task Force recommends the incorporation of DETECT, TTE or FVC/*D*~LCO~ ratio with elevated NT-proBNP to screen for SSc spectrum disorders. Although the prevalence of PAH is lower in those with *D*~LCO~ ≥80% of predicted, review of two large cohorts in the USA (\[[@C33]\] and Steve Mathai, Johns Hopkins, Baltimore, MD, USA; personal communication) suggested that PAH is present in these patients.

### Recommendations {#s4a1}

-   For patients with SSc and SSc spectrum with uncorrected *D*~LCO~ \<80% of predicted, annual screening should be considered. The appropriate screening tools include DETECT, the 2015 ESC/ERS recommendations for TTE or FVC/*D*~LCO~ ratio \>1.6 (assuming none-to-mild interstitial lung disease) and \>2-fold upper limit of normal of NT-proBNP. If any of these screening tests are positive, these patients should be referred for RHC. For those with uncorrected *D*~LCO~ ≥80% of predicted, screening may be considered with TTE.

HIV {#s4b}
---

Although the incidence of PAH in HIV is low, the large number of HIV-infected individuals worldwide makes HIV a major contributor to the worldwide incidence of PAH and a significant contributor to HIV-related death. Prior guidelines did not recommend PAH screening in HIV-infected patients, a conclusion derived from contemporary RHC-based studies in Europe \[[@C34]\] and the USA \[[@C35]\].

Preliminary data from an ongoing RHC-based study in Atlanta HIV clinics suggests a higher incidence of PH than previously reported in the USA (prevalence 2% in this US-based African-American population) (Marshaleen Henriques-Forsythe, Morehouse School of Medicine, Atlanta, GA, USA and Harrison W. Farber, Pulmonary Center, Boston University School of Medicine, Boston, MA, USA; personal communication). Risks for PAH in HIV include sex and *i.v.* drug use. Males are more frequently infected with HIV than females, but HIV-infected females are disproportionately diagnosed with PAH (around 2-fold). Intravenous drug use has been associated with HIV-PAH \[[@C36]\] in univariate analysis, although it dropped out in multivariate analysis; however, a biological rationale for this association has been demonstrated \[[@C37]\]. Data suggest that cocaine acts synergistically with the HIV-1 Tat (transactivator of transcription) protein \[[@C38]\] by suppressing bone morphogenetic protein receptor expression on pulmonary artery smooth muscle cells.

Other studies report an association between HIV-PAH and female sex \[[@C39]\], chronic hepatitis C virus infection (multivariate OR 3.01, 95% CI 1.2--8.2; p=0.02 \[[@C21], [@C40]\]) and origin from high-prevalence country \[[@C41]\].

The following higher-risk features are proposed for PAH screening in HIV to enrich the likelihood of earlier diagnosis of HIV-PAH in asymptomatic patients: female sex, *i.v.* drug use/cocaine use, hepatitis C virus infection, origin from high-prevalence country, known Nef (negative regulatory factor) or Tat HIV proteins and US African-American patients independent of symptoms.

### Recommendations {#s4b1}

-   Screen for PAH in HIV patients with symptoms or with more than one risk factor for HIV-PAH.

Heritable {#s4c}
---------

Recommendations in the USA for PAH genetic screening are largely ignored, misunderstood or unfunded \[[@C42]\]. In contrast, genetic screening and counselling offered by French PH referral centres have identified PAH mutations in 16.9% of presumed sporadic PAH patients, in 89% of patients with a family history \[[@C43]\] and in asymptomatic first-degree relatives of mutation carriers pre-emptively screened. Recent longevity data indicates a lifelong risk of developing disease in 14% of male and 42% of female carriers, prompting our recommendation for annual echocardiography in asymptomatic carriers \[[@C44]\].

### Recommendations {#s4c1}

-   Genetic counselling of all idiopathic, anorexiant and familial PAH patients and first-generation asymptomatic family members of patients with known genetic mutations.

-   Subsequent evaluations for PAH should be offered (*e.g.* CPET and TTE), in mutation-positive individuals.

-   National databases for genotyping all PAH patients should be advocated by the WSPH. Biobanking of samples and/or genotyping should be mandated in future interventional studies in PAH patients and possibly in PH patients.

Other heritable PH {#s4d}
------------------

### Hereditary haemorrhagic telangiectasia {#s4d1}

The French hereditary haemorrhagic telangiectasia (HHT) registry \[[@C45]\] demonstrated the echocardiographic prevalence of PH in HHT as 4.23%, although this was usually associated with high-output left heart failure. However, the review indicated that while PAH was rare, it was associated with much poorer survival.

#### Recommendations {#s4d1a}

-   In symptomatic patients and those with heart failure or hepatic arteriovenous malformations, with HHT or family history of HHT, genetic testing and an echocardiogram should be undertaken. If TTE positive ([tables 1](#TB1){ref-type="table"} and 2) or suggestive of PH, RHC should be undertaken to distinguish the aetiology of PH.

### Portopulmonary hypertension {#s4d2}

The frequency of PH in patients with liver disease varies with disease severity and duration. By time of liver transplantation 10.3% of patients had RHC-proven mean pulmonary arterial pressure (mPAP) \>35 mmHg \[[@C46]\]. A retrospective review of the UK National Registry of all incident treatment-naive patients with POPH suggested a prevalence of 0.85 cases per million population \[[@C47]\]. The prevalence of POPH in the portal hypertensive population has been previously estimated as 2--6%. Estimated median survival time was 3.75 years in this patient population, with 1-, 2-, 3- and 5-year survival of 85%, 73%, 60% and 35%, respectively.

#### Recommendations {#s4d2a}

-   Echocardiographic screening is recommended in all patients with portal hypertension. If a tricuspid regurgitant jet of \>3.4 m·s^−1^ or right atrial or right ventricular enlargement or dysfunction is found, then further evaluation with RHC and referral to PH expert centre is recommended.

### Congenital heart disease {#s4d3}

In CHD, PAH can be identified in four distinct subgroups of patients: 1) Eisenmenger syndrome, 2) persistent systemic-to-pulmonary shunts, 3) those with small, coincidental defects, and 4) patients who have undergone defect correction. PAH is present by definition in subgroups 1 and 3. Thus, PAH screening in the CHD population should be undertaken in subgroup 2 and, importantly, subgroup 4.

#### Recommendations {#s4d3a}

-   Post-operative PAH screening in subgroup 4 should include clinical and echocardiographic and ECG screening during follow-up visits 3--6 months after correction and then throughout their planned long-term cardiological follow-up. *Annual screening should be planned for corrected patients who presented with increased baseline pulmonary vascular resistance or with combinations of other predisposing factors*.

Novel diagnostic modalities {#s5}
===========================

Innovative imaging {#s5a}
------------------

### *V/Q* single photon emission CT {#s5a1}

*V/Q* single photon emission CT (SPECT) has higher sensitivity compared with planar imaging and outcome studies have confirmed a high negative predictive value in excluding pulmonary embolism \[[@C48], [@C49]\].

Dual-modality techniques with varying combinations of hybrid SPECT/CT pulmonary imaging can improve the specificity of *V/Q* SPECT by identifying lung diseases in patients with perfusion abnormalities. The addition of low-dose CT improves the specificity of *V/Q* SPECT from 88% to 100% while maintaining the same high sensitivity of 97% \[[@C50]\]. *V/Q* SPECT reduces radiation exposure relative to CT \[[@C51]--[@C53]\].

The three-dimensional aspects of *V/Q* SPECT allow for data objectification and facilitate automated analysis. The perfusion redistribution index as measured by *V/Q* SPECT showed perceptible reduction in the normal gravity-dependent redistribution of lung perfusion in PAH patients compared with the normal population \[[@C54]\] and hence can be a potential marker of pulmonary vascular disease.

*V/Q* SPECT and hybrid pulmonary imaging are not universally available.

### Dual-energy CT: pulmonary perfusion {#s5a2}

Dual-energy CT (DECT) offers visualisation of morphological and perfusion abnormalities in the pulmonary vasculature. Perfusion alterations were less common but more homogeneous in PAH and were mainly in the form of patchy defects \[[@C55]\]. In CTEPH, perfusion alterations were more frequent and heterogeneous with a high level of concordance with *V/Q* scintigraphy. The utility of DECT in the diagnosis and prognosis of PH, particularly CTEPH, requires further evaluation.

### Three-dimensional dynamic contrast-enhanced magnetic resonance: lung perfusion {#s5a3}

Dynamic contrast-enhanced magnetic resonance estimates of perfusion are based on quantification of tissue enhancement at serial time-points after injection of gadolinium and the technique has comparable sensitivity to perfusion scintigraphy for diagnosing CTEPH \[[@C56], [@C57]\]. Although the lack of ionising radiation makes this an attractive alternative, limited availability and higher costs preclude this technique from superseding *V/Q* scintigraphy.

### Functional magnetic resonance imaging: ventilation {#s5a4}

The ready availability and ease of inhaled oxygen as a contrast medium makes pulmonary magnetic resonance imaging (MRI) a promising tool for assessing ventilation. In a small study, oxygen-enhanced ventilation and contrast-enhanced perfusion MRI was concordant with scintigraphy \[[@C58]\]. Standardisation of analyses and reproducibility of oxygen-enhanced MRI metrics is needed before routine use in clinical practice.

### Subclinical right ventricular dysfunction {#s5a5}

#### Parametric mapping {#s5a5a}

A review of the magnetic resonance literature found 21 magnetic resonance metrics indicative of PH \[[@C59]\]. Of these, the ventricular mass index (VMI) was frequently used to assess right ventricular functional and structural changes compared with RHC. A meta-analysis of VMI revealed a positive likelihood ratio of 4.894, indicating a modest ability to differentiate PH patients from healthy controls.

Late gadolinium enhancement (LGE) at the right ventricular insertion points in PH due to delayed clearance of gadolinium correlates inversely with right ventricular performance \[[@C60]\]; however, its utility has been called into question in recent studies as a prognostic indicator in PH \[[@C61]\].

T~1~ mapping is a non-invasive technique for extracellular volume (ECV) quantification and facilitates early detection of myocardial involvement that is not detectable by LGE. PH has been shown in a small study to be independently associated with increased right ventricular ECV even after adjustment for right ventricular dilatation and dysfunction \[[@C62]\].

Larger studies are required to determine if right ventricular ECV reliably predicts adverse clinical outcomes, offering the potential for risk stratification, prognostication and therapeutic efficacy assessment.

#### Right ventricular strain {#s5a5b}

Cardiac magnetic resonance-based right ventricular strain imaging evaluates regional myocardial function by measuring the percentage change in myocardial deformation. Cardiac magnetic resonance feature tracking has shown a significant reduction in right ventricular strain in PH patients with normal right ventricular ejection fraction, predicting subsequent clinical deterioration \[[@C63]\]. Magnetic resonance strain indices are similar to echocardiographic indices, but longitudinal and circumferential strain measurements are more reliable.

### Pulmonary artery four-dimensional flow imaging {#s5a6}

Time-resolved three-dimensional phase-contrast MRI, also known as four-dimensional flow magnetic resonance, visualises and quantifies cardiovascular blood flow. The pulmonary artery flow patterns can be a non-invasive early marker in those at risk for developing PH.

Main pulmonary artery flow vortices are a marker of elevated mPAP. Vortical blood flow in the main pulmonary artery \>14.3% of the cardiac interval corresponds to PH with 97% sensitivity and 96% specificity \[[@C64]\]. The duration of the vortical flow shows a linear increase with mPAP and can be used to estimate PAPs \[[@C65]\]. Early onset of retrograde flow in the dorsal aspect of the main pulmonary artery is another characteristic of PAH \[[@C66]\].

Wall shear stress is reduced in the proximal pulmonary arteries of PAH patients, and may contribute to pulmonary endothelial cell dysfunction and PAH progression \[[@C67]\]. Wall shear stress can be characterised by four-dimensional flow magnetic resonance with the ability to discriminate PAH patients from normal controls \[[@C68]--[@C70]\].

These metrics are not available from routine RHC and therefore have potential for non-invasive PH screening and monitoring. Data extraction is complex and clinical trials are necessary to explore the benefits of four-dimensional flow magnetic resonance over standard practices.

Intravascular ultrasound and optical coherence tomography in PAH {#s5b}
----------------------------------------------------------------

Intravascular ultrasound and optical coherence tomography (OCT) can demonstrate intimal fibrosis, a surrogate marker of pulmonary arterial remodelling that correlates negatively with pulmonary arterial compliance and is associated with unfavourable clinical outcomes during mid-term follow-up \[[@C71]\]. OCT has shown development of pulmonary arterial remodelling in patients with borderline PH and the occurrence of reverse remodelling following effective treatment \[[@C72]\].

Machine learning {#s5c}
----------------

Technological advances in cardiac imaging coupled with exceptional computing power and innovative analytical modelling offer an unprecedented amount of data that can contribute to the search for novel imaging biomarkers.

A recently published machine learning-based survival model had incremental prognostic power when compared with conventional parameters to more accurately predict outcomes in PH \[[@C73]\]. Such computational simulations can illuminate pathophysiological mechanisms of right ventricular failure, risk stratify different PH groups and identify imaging end-points following therapeutic interventions.

Future biomarkers {#s5d}
-----------------

Numerous potential biomarkers (*e.g.* asymmetric dimethylarginine, cystatin C, volatile exhaled gases, exhaled nitric oxide (NO) fraction (*F*~ENO~) and NO*~x~* derivates) \[[@C74]\] have been associated with endothelial cell dysfunction, inflammation, epigenetics, cardiac function, oxidative stress, metabolism, extracellular matrix and exhaled breath condensate \[[@C75], [@C76]\]; while novel, these have not yet demonstrated sensitivity and specificity for diagnosis, risk assessment or management of PH.

The future of laboratory biomarkers may hinge on the ability to use "deep phenotyping", *i.e.* characteristic patterns in the genome, transcriptome, proteome and/or metabolome of the patient \[[@C77]--[@C81]\]. Currently metabolomics emerges as a potentially informative area of systems biology. In the future, a metabolomics fingerprint may inform treatment decisions, while changes may be considered "deep monitoring" of treatment results. Currently, however, abnormal responses *versus* normal responses to abnormal stimuli are indistinguishable and metabolic signatures have only been evaluated in well-defined, homogenous study populations. New research paradigms are necessary to prove their value for early detection and differential diagnosis of PAH in real life.
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